Open AccessObservational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
Author(s) -
James Sun,
Brian Gastman,
Lucy McCahon,
Elizabeth I. Buchbinder,
Igor Puzanov,
Michele Nanni,
James M. Lewis,
Richard D. Carvajal,
Shahnaz Singh-Kandah,
Anupam M. Desai,
Leon Raskin,
Carrie M. Nielson,
Rubina Ismail,
Jonathan S. Zager
Publication year - 2020
Publication title -
melanoma management
Language(s) - English
Resource type - Journals
eISSN - 2045-0893
pISSN - 2045-0885
DOI - 10.2217/mmt-2020-0005
Subject(s) - medicine , discontinuation , context (archaeology) , melanoma , metastatic melanoma , oncology , surgery , cancer research , paleontology , biology
Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma. T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization. Materials & methods: A retrospective review of T-VEC use from 1 January 2017 and 31 March 2018 for melanoma patients was conducted at seven US institutions. Results: Among 83 patients, three categories of T-VEC and anti-PD-1 therapy were identified: T-VEC used without anti-PD-1 (n = 29, 35%), T-VEC after anti-PD-1-based therapy (n = 22, 27%) and concurrent T-VEC and anti-PD-1-based therapy (n = 32, 39%). 25% of patients discontinued T-VEC therapy due to no remaining injectable lesions, 37% discontinued T-VEC due to progressive disease. Discontinuation of T-VEC did not differ by anti-PD-1-based therapy use or timing. Conclusion: In real-world settings, T-VEC may be used concurrently with or after anti-PD-1-based therapy.